I. MODIFIED AGREEMENTS | |||
Biotech Co.* |
Pharma Co. |
Change from original |
Terms/Details (Date) |
| | |||
Gene Logic |
Daiichi Pharmaceutical Co. Ltd. (Japan) |
Daiichi continued its subscription to the BioExpress System |
The focus of the multiyear subscription is primarily for discovery research; terms of the deal were not disclosed (6/7) |
Gene Logic |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Takeda extended its subscription to the BioExpress System |
Takeda extended access through 2006 for use in drug discovery and development; terms of the deal were not disclosed (6/7) |
GW |
Bayer HealthCare AG (Germany) |
They amended marketing deal on Sativex in the UK and Canada, after the product was approved in Canada first |
Some details were changed, but milestone payments of £32.75M due to GW remain unchanged (5/11) |
Indevus |
Pliva d.d. (Croatia) |
Saturn Pharmaceuticals Inc. acquired rights to market Sanctura from Odyssey Pharmaceuticals Inc. |
Odyssey, a Pliva subsidiary, had acquired rights in April 2004; Indevus gets enhanced economic terms under the amended deal (5/16) |
II. TERMINATED AGREEMENTS | |||
Genta Inc. (GNTA) |
Sanofi-Aventis Group (France) |
They formally terminated their deal to develop Genta's cancer drug Genasense |
Sanofi provided notice of the termination in November 2004; there are no further financial obligations between them (5/10) |
NeoPharm Inc. |
Akorn Inc. |
They ended a deal under which NeoPharm had access to manufacturing capacity at an Akorn facility |
The deal granting capacity to NeoPharm was signed in 2002; NeoPharm already made arrangements for its manufacturing needs (5/16) |
| | |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange. | |||
